Annie Delaunois

Director, Head of Safety & Secondary Pharmacology

Belgium

Research Interests

Explore related searches

Professors in Belgium

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (3)

Margot Ernst

Associate Professor

Medical University of Vienna Center for Brain Research

AUSTRIA

View details

Filip Tadeusz Koniuszewski

Medical University of Vienna

AUSTRIA

View details

Florian Daniel Vogel

Universität Wien

AUSTRIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Annie Delaunois

Research Interests

Explore related searches

Contact this professor

Articles (10)

Assessing the interplay between off-target promiscuity, cytotoxicity, and tolerability in rodents to improve the safety profile of novel anti-malarial plasmepsin X inhibitors

Deconvoluting and derisking QRS complex widening to improve cardiac safety profile of novel plasmepsin X antimalarials

Author Correction: The state of the art in secondary pharmacology and its impact on the safety of new medicines

Results from a Joined Prospective Study to Evaluate the Sensitivity of the In Vivo Dog QT Assay in Line with the ICH E14/S7B Q&A Best Practices

The state of the art in secondary pharmacology and its impact on the safety of new medicines

GABAA receptor-mediated seizure liabilities: a mixed-methods screening approach

Comparative study for the IMI2-NeuroDeRisk project on microelectrode arrays to derisk drug-induced seizure liability.

"Appraisal of state-of-the-art" The 2021 Distinguished Service Award of the Safety Pharmacology Society: Reflecting on the past to tackle challenges ahead.

Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As.

Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti‐seizure medication: Levetiracetam case study

Collaborators (3)

Margot Ernst

Filip Tadeusz Koniuszewski

Florian Daniel Vogel

Make your next move.